<DOC>
	<DOCNO>NCT03003546</DOCNO>
	<brief_summary>This phase I trial study best dose side effect paclitaxel albumin-stabilized nanoparticle formulation ( nab-paclitaxel ) /rituximab-coated nanoparticle AR160 treat patient B-cell non-Hodgkin lymphoma come back respond treatment . Nab-paclitaxel/rituximab-coated nanoparticle AR160 combination paclitaxel albumin-stabilized nanoparticle formulation rituximab . Drugs use chemotherapy , paclitaxel albumin-stabilized nanoparticle formulation , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Monoclonal antibody , rituximab , may interfere ability tumor cell grow spread . Giving paclitaxel albumin-stabilized nanoparticle formulation rituximab may work well treat patient B-cell non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 Treating Patients With Relapsed Refractory B-Cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To establish maximum tolerate dose ( MTD ) nab-paclitaxel/rituximab-coated nanoparticle AR160 ( AR160 ) patient relapsed/refractory B-cell non-Hodgkin lymphoma ( NHL ) . ( Phase I ) SECONDARY OBJECTIVES : I . To assess toxicity safety AR160 . II . To assess complete response rate ( CR ) progression free survival ( PFS ) , overall survival ( OS ) AR160 relapsed/refractory B-cell NHL . TERTIARY OBJECTIVES : I . Evaluate pharmacokinetics ( PK ) AR160 two formal PK study , dose 1 cycle 1 ( 48 hour [ h ] PK analysis ) dose 1 cycle 2 ( 24h PK analysis ) . OUTLINE : This dose-escalation study . Patients receive nab-paclitaxel/rituximab-coated nanoparticle AR160 intravenously ( IV ) 30-60 minute day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histological confirmation relapsed/refractory Bcell NHL , CD20+ NOTE : patient small lymphocytic lymphoma ( SLL ) eligible however patient chronic lymphocytic leukemia ( CLL ) eligible Waldenstrom macroglobulinemia patient eligible ; aggressive lymphoma patient transplant eligible must undergo transplant The biopsy confirm relapse 24 week prior registration long intervene therapy Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 Absolute neutrophil count ( ANC ) &gt; = 1500/mm^3 Platelet count &gt; = 75,000/mm^3 Hemoglobin &gt; = 8.0 g/dL Total bilirubin = &lt; 1.5 X upper limit normal ( ULN ) total bilirubin &gt; 1.5 X ULN , direct bilirubin = &lt; ULN Alkaline phosphatase = &lt; 3 X ULN unless due direct lymphoma involvement , = &lt; 5 X ULN Aspartate transaminase ( AST ) = &lt; 3 X ULN unless due direct lymphoma involvement , = &lt; 5 X ULN Calculated creatinine clearance must &gt; = 30 ml/min use CockcroftGault formula Life expectancy &gt; = 3 month Ability provide write informed consent Willing return enrol institution followup ( treatment observation phase study ) Willing provide tissue central review blood sample correlative research purpose No therapy demonstrate clinical benefit relapsed/refractory Bcell NHL available patient Negative pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Any following : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Active central nervous system ( CNS ) lymphoma cerebrospinal fluid involvement malignant lymphoma cell require therapy Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Patients receive recent therapy = &lt; 4 week prior registration ; NOTE : use systemic steroid therapy allow pretreatment Receiving investigational agent would consider treatment primary neoplasm Patients must diseasefree prior invasive malignancy &gt; 5 year prior registration exception curativelytreated basal cell squamous cell carcinoma skin carcinoma situ cervix Patients &gt; = 25 % bone marrow radiate diseases Other medical condition include limited : History liver disease cirrhosis , chronic active hepatitis , chronic persistent hepatitis hepatitis B C Active infection require parenteral antibiotic New York Heart Association class IIIV congestive heart failure ( serious cardiac arrhythmia require medication ) Myocardial infarction unstable angina = &lt; 6 month prior registration Congestive heart failure require use ongoing maintenance therapy lifethreatening ventricular arrhythmia Clinically significant peripheral vascular disease History CNS disease ( e.g. , primary brain tumor , vascular abnormality , etc . ) , clinically significant stroke transient ischemic attack ( TIA ) = &lt; 6 month prior registration , seizures control standard medical therapy Neuropathy Ëƒ grade 3 Administration strong CYP2C8 CYP3A4 inhibitor inducer = &lt; 10 day prior registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>